US-based CiceroDx has introduced a new test panel called ReceptivaDx to diagnose causes of unexplained infertility in women.

With the new test, the firm intends to provide a cost-effective solution for in-vitro fertilisation (IVF) centres and healthcare providers to detect barriers to implantation such as endometriosis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Reportedly, 15-30% of women undergoing evaluation for infertility have an unidentified cause, and endometriosis is said to be associated with around 50% of all unexplained infertility cases.

The new ReceptivaDx assay uses an endometrial biopsy sample and delivers results in three to five days, unlike existing diagnostic techniques that require the use of an expensive and invasive surgical procedure called laparoscopy to identify endometriosis.

The early identification of the condition is expected to assist IVF centres in determining appropriate treatment options, leading to an increase in success rates.

"The new ReceptivaDx assay uses an endometrial biopsy sample and delivers results in three to five days."

CiceroDx CEO Chris Jackson said: “Our mission at CiceroDx is to ensure we deliver the most accurate and cost-effective diagnostic tools for doctors and families looking for answers to unexplained infertility and implantation failure.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Helping resolve infertility issues is just the first step. Our goal is to help clinicians better detect endometriosis in the millions of women who suffer from this silent epidemic every day.”

The firm holds the exclusive licence to distribute and market the ReceptivaDx test.

CiceroDx scientific advisor Bruce Lessey further added: “ReceptivaDx is a breakthrough test and provides a unique, enhanced screening opportunity."

The test is currently available at more than 75 IVF centres in the US, Canada, Europe and South America.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact